Completed PHASE3 INTERVENTIONAL 2-arm NCT00987454

Erythropoietin in Traumatic Brain Injury (EPO-TBI) (EPO-TBI)

A Randomised, Placebo-controlled Trial of Erythropoietin in ICU Patients With Traumatic Brain Injury

Sponsor: Australian and New Zealand Intensive Care Research Centre

Interventions Epoetin Alfa Sodium Chloride 0.9%

Updated 5 times since 2017 Last updated: Jul 24, 2016 Started: May 31, 2010 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Traumatic Brain Injury, this trial is completed. The trial is conducted by Australian and New Zealand Intensive Care Research Centre and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Australian and New Zealand Intensive Care Research Centre
Australian and New Zealand Intensive Care Society Clinical Trials Group
Monash University
National Health and Medical Research Council, Australia

Data source: Australian and New Zealand Intensive Care Research Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Auckland, New Zealand , Camperdown, Australia , Canberra, Australia , Christchurch, New Zealand , Darlinghurst, Australia , Dublin, Ireland , Dunedin, New Zealand , Grenoble, France , Helsinki, Finland and 16 more locations